Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study

Abstract Introduction This study aimed to report bimekizumab (BKZ) efficacy and safety in Japanese patients with generalised pustular psoriasis (GPP) and erythrodermic psoriasis (EP). Methods Patients aged ≥ 18 years with plaque psoriasis, GPP, or EP received BKZ for 144 weeks; only results for GPP...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Yukari Okubo, Yayoi Tada, Hidetoshi Takahashi, Masatoshi Abe, Keiichi Yamanaka, Nicola Tilt, Nancy Cross, Delphine Deherder, Mizuho Matano, Hidemi Nakagawa
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Adis, Springer Healthcare 2025-08-01
Cyfres:	Dermatology and Therapy
Pynciau:	Anti-interleukin-17 Bimekizumab Erythrodermic psoriasis Generalised pustular psoriasis Japan
Mynediad Ar-lein:	https://doi.org/10.1007/s13555-025-01509-9
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!